文献速递头颈技术与安全PETCT

FDG PET-CT最大标准化摄取值变化在头颈部鳞状细胞癌放化疗后监测中的作用:初步发现

The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings.
PubMed 文献 · Br J Radiol · 2017-01-05

本研究纳入40例接受放化疗的头颈部鳞状细胞癌患者,于治疗前及放化疗后3个月行PET-CT并随访2年,评估原发肿瘤和转移淋巴结的ΔSUVmax与复发、复发时间及生存的关系。原发肿瘤ΔSUVmax在复发组显著低于非复发组,与复发时间相关,阈值1.04区分复发与非复发的敏感度为76.9%、特异度为86.4%。

要点

  • 原发肿瘤ΔSUVmax在复发组显著低于非复发组(原发部位p=0.007,淋巴结部位p=0.02)。
  • 原发肿瘤ΔSUVmax阈值1.04区分复发与非复发:敏感度76.9%、特异度86.4%。
  • 转移淋巴结ΔSUVmax与复发及患者生存无显著关联。

核心结论

  • 原发肿瘤ΔSUVmax与复发及患者生存显著相关,可能是有助于头颈部鳞状细胞癌放化疗后监测管理决策的临床参数。

研究设计与样本

  • 初步研究,40例接受放化疗的头颈部鳞状细胞癌患者,于治疗前及放化疗后3个月行PET-CT,随后序贯PET-CT随访2年。
  • 计算原发肿瘤和转移淋巴结在治疗前与放化疗后3个月之间的ΔSUVmax,评估其与复发表现、复发时间及患者生存的关联。

诊断标准与关键数值

  • 原发肿瘤ΔSUVmax阈值1.04区分复发与非复发的敏感度为76.9%、特异度为86.4%。
  • 原发肿瘤ΔSUVmax在复发组显著低于非复发组:原发部位p=0.007,淋巴结部位p=0.02。
  • 复发时间与原发肿瘤ΔSUVmax显著相关(r=0.63,p<0.05)。
  • 按原发肿瘤ΔSUVmax 1.04分组的无进展生存和总生存差异显著(p=0.003,p=0.02)。
  • 转移淋巴结ΔSUVmax与复发或患者生存无显著关联。

临床应用与阅片要点

  • 作者认为原发肿瘤ΔSUVmax可能是有助于头颈部鳞状细胞癌放化疗后监测管理决策的有效临床参数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: No clear consensus exists regarding the optimal interval and frequency of follow-up positron emission tomography (PET)-CT in patients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiotherapy (CRT). Here, we sought to clarify whether the changes in the maximum standardized uptake value (ΔSUVmax) may be a valid parameter to help decision-making for surveillance management after CRT.

METHODS: 40 patients underwent PET-CT at pre-treatment and 3 months after CRT. Patients were followed by sequential PET-CT for 2 years after CRT. The ΔSUVmax of the primary tumour and the metastatic nodes were calculated between pre-treatment and 3 months after the CRT, and we evaluated the associations between ΔSUVmax and the manifestation of recurrence, time to recurrence and the patient survival.

RESULTS: The ΔSUVmax of the primary tumour was significantly lower for the lesions with recurrence than that for those with non-recurrence for both the primary site and the nodal site (p = 0.007, 0.02). A significant correlation was found between the time to recurrence and the ΔSUVmax of the primary tumour (r = 0.63, p < 0.05). The threshold ΔSUVmax of the primary tumour of 1.04 revealed 76.9% sensitivity and 86.4% specificity for distinguishing recurrence from non-recurrence. The progression-free survival and overall survival of the two patient groups divided by the ΔSUVmax of the primary tumour at 1.04 showed a significant difference (p = 0.003, 0.02). The ΔSUVmax of the metastatic nodes did not show a significant association with recurrence or patient survival.

CONCLUSION: The ΔSUVmax of the primary tumour showed a significant association with recurrence and patient survival. Advances in knowledge: The ΔSUVmax of the primary tumour may be a valid clinical parameter to help decision-making for the surveillance management of patients with HNSCC after CRT.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Matoba M, Tuji H, Shimode Y, et al. The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings. Br J Radiol. 2017. PMID: 28055245. doi:10.1259/bjr.20150404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。